Malignant Ascites Clinical Trials

A listing of Malignant Ascites medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.

  • 0 views
  • 27 Apr, 2022
  • 1 location
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites

malignant ascites, and determine the recommended number of doses for Phase II part. Phase II Part : Research the efficacy and safety of as a single agent or GAIA-102 and pembrolizumab for

adenocarcinoma
gastric adenocarcinoma
drainage
gastrointestinal cancer
pancreatic cancers
  • 0 views
  • 11 Jul, 2022
  • 1 location
A Phase Ia/Ib, Open-label, Single-arm, Dose-escalation and Expansion Study of Specific Dual-targeting VEGFR1 and PD-L1 CAR-T in Cancer Patients With Pleural or Peritoneal Metastases

Serosal cavity metastases of malignant tumor seriously affects the quality of life and survival time of patients with cancers in advanced stage. VEGFR1 is frequently expressed in breast cancer, ovarian cancer, lung cancer, gastric cancer and other malignant tumors and their metastases. The VEGFR1/PD-L1 dual-targeting CAR-T will be investigated in …

  • 0 views
  • 14 Oct, 2022
  • 1 location
An Open Label, Randomized Controlled Clinical Study on the Safety and Efficacy of Virus Activated Killer Immune Cells (VAK) in the Treatment of Malignant Pleural and Peritoneal Effusion

Theory of VAK: Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells. They could be restimulated by virus antigen, and play a powerful tumor killing role while intrapleural to subjects. Releasing of tumor-associated antigen could …

tumor cells
malignant pleural effusion
cancer
anti-coagulant
  • 0 views
  • 25 Oct, 2022
  • 1 location
International Alfapump Cohort Study (TOPMOST)

This Registry is designed to follow patients who have been implanted with an alfapump system, which is a newly marketed product from Sequana Medical AG, a Swiss Medical Device company.

  • 90 views
  • 03 Mar, 2022
  • 2 locations
Mass Response of Malignant Fluid Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from malignant fluids such as pleural effusions and ascites.

pleural effusion
carcinoma
drainage
ascites
combinations
  • 2 views
  • 22 Oct, 2022
  • 1 location
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

The primary objective of this study, sponsored by Travera LLC in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats. Cohorts include patients with stage III or …

carcinoma
lung cancer
cancer
breast cancer
combinations
  • 0 views
  • 20 Oct, 2022
  • 1 location
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer (LIPAC)

Pancreatic cancer (PC) is a deadly disease and surgical resection of the tumor is the only hope of cure. Approximately 20-25% of the PC patients are candidates for intended curative resection, but despite microscopically radical resection the majority of patients will have recurrent disease within 2 years. This indicates that …

cancer chemotherapy
adenocarcinoma
pancreatic resection
tumor cells
pdac
  • 0 views
  • 16 Jun, 2022
  • 1 location